Evidence map›Paper›PMID 27597434›Full record

ArticleCellular microbiology2017

Two lytic transglycosylases in Neisseria gonorrhoeae impart resistance to killing by lysozyme and human neutrophils.

Stephanie A Ragland, Ryan E Schaub, Kathleen T Hackett, Joseph P Dillard, Alison K Criss

Abstract read
In one paragraph

Article in Cellular microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Effects of SupergroundAnimals : an open access journal from MDPI · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Peptidoglycan deacetylation controls type IV secretion and the intracellular survival of the bacterial pathogenProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Immune responses toFrontiers in immunology · 2023
    Review
  15. Review
  16. Article
  17. Article
  18. Anti-Virulence Therapeutic Approaches forAntibiotics (Basel, Switzerland) · 2021
    Review
  19. Review
  20. A NovelFrontiers in microbiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Stephanie A RaglandDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, 22908, USA.
Ryan E SchaubDepartment of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin, 53706, USA.
Kathleen T HackettDepartment of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin, 53706, USA.
Joseph P DillardDepartment of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin, 53706, USA.
Alison K CrissDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, 22908, USA.
University of Wisconsin–Madison · USUniversity of Virginia · US

Funding

INFECTIOUS DISEASES TRAINING PROGRAMT32AI007046 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Alison K Criss, William A Petri · 1985 to 2026
$15.3M
Peptidoglycan metabolism and fragment releaseR01AI097157 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI DILLARD, JOSEPH P · 2012 to 2022
$5.6M
Survival of Neisseria gonorrhoeae after primary human neutrophil challengeR01AI097312 · NIAID · UNIVERSITY OF VIRGINIA · PI CRISS, ALISON K · 2012 to 2022
$4.6M
Survival of Neisseria gonorrhoeae after primary human neutrophil challengeR37AI097312 · NIAID · UNIVERSITY OF VIRGINIA · PI Alison K Criss · 2025 to 2026
$1.1M
ImageSteamXS10RR031633 · NCRR · UNIVERSITY OF VIRGINIA · PI BENDER, TIMOTHY P. · 2011 to 2011
$520k
NCRR NIH HHS S10 RR031633NIAID NIH HHS R01 AI097157NIAID NIH HHS R01 AI097312NIAID NIH HHS R37 AI097312NIAID NIH HHS T32 AI007046
6 · The paper itself

Abstract

Symptomatic infection by Neisseria gonorrhoeae (Gc) produces a potent inflammatory response, resulting in a neutrophil-rich exudate. A population of Gc can survive the killing activities of neutrophils for reasons not completely understood. Unlike other Gram-negative bacteria, Gc releases monomeric peptidoglycan (PG) extracellularly, dependent on two nonessential, nonredundant lytic transglycosylases (LTs), LtgA and LtgD. PG released by LtgA and LtgD can stimulate host immune responses. We report that ΔltgAΔltgD Gc were decreased in survival in the presence of primary human neutrophils but otherwise grew equally to wild-type Gc. Adding PG monomer failed to alter ΔltgAΔltgD Gc survival. Thus, LTs protect Gc from neutrophils independently of monomer release. We found two reasons to explain decreased survival of the double LT mutant. First, ΔltgAΔltgD Gc was more sensitive to the neutrophil antimicrobial proteins lysozyme and neutrophil elastase, but not others. Sensitivity to lysozyme correlated with decreased Gc envelope integrity. Second, exposure of neutrophils to ΔltgAΔltgD Gc increased the release of neutrophil granule contents extracellularly and into Gc phagosomes. We conclude that LtgA and LtgD protect Gc from neutrophils by contributing to envelope integrity and limiting bacterial exposure to select granule-localized antimicrobial proteins. These observations are the first to link bacterial degradation by lysozyme to increased neutrophil activation.

Indexed as

Microbial ViabilityAnti-Infective AgentsGene DeletionHumansMuramidaseNeisseria gonorrhoeaeNeutrophilsPeptidoglycanPeptidoglycan GlycosyltransferaseAnti-Infective AgentsMuramidasePeptidoglycanPeptidoglycan Glycosyltransferase

Identifiers

PMID27597434
PMCPMC5303151
OpenAlexW2508251718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.